Unilife — Earnings Presentation (July 2015)
23 slides from Unilife's earnings presentation, Jul 30, 2015
Slide 1: Unilife Conference Call
Exhibit 99.1 Unilife Conference Call July 30, 2015
Slide 2: Cautionary Note Regarding Forward-Looking Statements
Cautionary Note Regarding Forward-Looking Statements This presentation dated July 30, 2015 has been prepared by Unilife Corporation ("Unilife or Company") (NASDAQ: UNIS; ASX: UNIS). Statements and information in this presentation are current only as at July 30, 2015 and the information in this prese
Slide 3: Agenda and Introduction
Agenda and Introduction • Customer programs continue to move forward favorably • Manufacturing and selling products across multiple product platforms • From a small base, sales of prefilled syringes and wearable injectors are increasing in line with customer ramp schedules • Well positioned for cont
Slide 4: Unifill Shipments Increasing to Fulfill Customer Orders
Unifill Shipments Increasing to Fulfill Customer Orders Assemblyline for the Unifill Finesse™ at Unilife’s facility in York,PA • 500,000 units shipped by end of quarter • 500,000 units expected to be shipped next quarter • Expanding production capacity to support scheduled customer orders • 100MM un
Slide 5: Wearable Injectors: Shipments to Commence for Scheduled Clinical Trials
Wearable Injectors: Shipments to Commence for Scheduled Clinical Trials • Continuing to be selected by customers for use with their large-dose volume therapies • Shipments for use in clinical trials scheduled to commence this quarter • Shipments for additional clinical trials by end of fiscal year •
Slide 6: Continued Investment in our Production Infrastructure in York, PA
Continued Investment in our Production Infrastructure in York, PA Doubling cleanroom space and expanding building footprint to support customer scale-up needs Installation of additional of cleanroom space in York, PA Additional cleanrooms to support specific customer needs Expansion of building foot
Slide 7: Financial Update
Financial Update Mr. David Hastings Chief Financial Officer
Slide 8: Market Segments and Product Portfolio for Injectable Drug Delivery
Market Segments and Product Portfolio for Injectable Drug Delivery Prefilled Syringes with Drug Reconstitution Auto- Wearable Ocular & Novel Delivery Automatic, Integrated Safety Delivery Systems Injectors Injectors Systems These products have not yet been reviewed by the FDA 25,000 Size and project
Slide 9: Market Segments and Product Portfolio for Injectable Drug Delivery
Market Segments and Product Portfolio for Injectable Drug Delivery Prefilled Syringes with Drug ReconstitutionInsulin Auto- Wearable Ocular & Novel Automatic, Integrated Safety Delivery SystemsDelivery Injectors Injectors Delivery Systems Size and projected growth for injectable drug $25,000 deliver
Slide 10: Diabetes is a Global Epidemic
Diabetes is a Global Epidemic “As many as one in three American adults will have diabetes in 2050 if present trends continue” American Diabetes Association Fact Sheet, June 2014 Global Diabetes Prevalence Staggering # • 1 in 11 adults (18+ years) has diabetes • Every7 seconds,1 persondies from diabe
Slide 11: Type 2 Diabetes Population: Underserved and Ready for New Technology
Type 2 Diabetes Population: Underserved and Ready for New Technology 20MM Insulin-Dependent Patients Worldwide Better Patient Outcomes Possible Two-Thirds in the U.S. and Europe But Not Achieved Through Current Therapeutic Offerings 12 - T2D Population Unaccepting of Traditional Pump Technology 6.4%
Slide 12: Economic Opportunity for Primary Market Category
Economic Opportunity for Primary Market Category Addressable Diabetes Populations Primary Target Market Segment Millions of Patients in U.S. and E.U. T2D Uncontrolled MDI 20 (IMS Health and Analyst Data) 2020 2025 2030 18 1.1 T1D 16 Uncontrolled 1.5 Patients 4,078,000 5,235,000 6,565,000 MDI 14 CSII
Slide 13: Economic Opportunity Growth with Other Segments
Economic Opportunity Growth with Other Segments Secondary Target Market Segment Tertiary Target Market Segment T2D Controlled MDI T1D Uncontrolled MDI and CSII 2020 2025 2030 2020 2025 2030 Patients 3,616,000 4,642,000 5,822,000 Patients 2,274,000 2,392,000 2,516,000 Market Share Potential Revenue M
Slide 14: Current Insulin Devices Fail to Meet Needs of Type 2 Patients
Current Insulin Devices Fail to Meet Needs of Type 2 Patients Multiple Daily Injections (MDI) • Multiple pieces of equipment • Disciplined dosing schedule required • Preparation time and risk of dosing to maintain therapy adherence error • Some patients require use of • Low use rate outside multiple
Slide 15: Key Technology Drivers in Insulin Delivery Market
Key Technology Drivers in Insulin Delivery Market • Simplify the steps to control the blood glucose Reduce level Complexity • Lower the barriers to therapy adoption and compliance • Decrease diabetes treatment burden by Empower improving therapy delivery and minimize patient health risk Patients • P
Slide 16: Introducing Imperium
Introducing Imperium™ Deliveringthe therapeuticadvantagesof a pump, with the simplicity and cost of a pen Criteria for an Instant Patch Pump for Insulin 1. Prefilled and pre-assembled with standard insulin cartridge 2. Fully functional stand-alone device (no ancillary equipment) 3. No priming requir
Slide 17: Imperium Platform – Features and Benefits for Patients
Imperium™ Platform – Features and Benefits for Patients Minimal Steps to Therapy Simple User Interface Supplied ready for use in a fully integrated system that is A preset basal rate with on-demand bolus via a simple prefilled with insulin. Just peel, stick and click. push of the button. No handheld
Slide 18: Peel. Stick. Click.
Simple Steps of Use to Begin Therapy Peel. Stick. Click. Peel liner from Apply device to Push button to device body start basal therapy 18
Slide 19: Comparing Steps to Therapy vs. Insulin Pens and Disposable Pumps
Comparing Steps to Therapy vs. Insulin Pens and Disposable Pumps Imperium Insulin Pens Insulin Pumps* 1 2 4+ Piece of equipment Pieces of equipment Pieces of equipment 3 12+ 20+ Steps to insulin therapy Steps per insulin injection Steps to insulin therapy * Including market-leading insulin patch pum
Slide 20: Press and Hold. Click.
Simple Steps of Use for Bolus Delivery Press and Press and Click. Hold. Hold. Press and hold button Click the button Press and hold button to enter bolus mode for bolus infusion to exit bolus mode 20
Slide 21: Additional Features and Benefits for Insulin Providers
Additional Features and Benefits for Insulin Providers U-100 U-300 U-500 Concentrated Insulins Standard Fill and Materials Prefilled, high-precision device capable of delivering Uses standard materials and integrates into established highly concentrated insulins up to U-500 filling processes and equ
Slide 22: Fits Seamlessly into Standard Fill Lines and Distribution Channels
Fits Seamlessly into Standard Fill Lines and Distribution Channels Fullyalignedwith Unilife’sB2BModelfor predictablerevenueandattractiveoperating margins Unilife Customer Pharmacy Patient • Supply sub-assemblies • Utilization of preferred • Imperium, pre-filled • Remove Imperium from to customer (no
Slide 23: Questions
Questions 23